Update on proposed acquisition of BioForLife Italia S.r.l, regulatory approval received

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

VIYASH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹261.95

prior close

₹261.00

announcement price

After-mkt

timing

Nifty Microcap 250market-0.2%+0.2% vs market

Pharmaceuticals peers, median of 174sector-0.2%+0.2% vs sector

On the reaction day the stock moved 0.2 pts more than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

+0.1

15m

-0.1

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0-0.2+0.2-0.2+0.2

Next day

-1.1-0.3-0.8-0.7-0.4

-1.9-0.2-1.6-0.7-1.2

-5.4-3.5-1.9-2.0-3.4

-8.6-3.6-4.9-2.4-6.2

-6.5-2.8-3.7-2.3-4.2

-4.0-1.4-2.6-0.8-3.2

15d

-11.4-3.0-8.4-2.1-9.3

-10.5-4.4-6.1-5.0-5.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Viyash Scientific's step-down subsidiary Alivira Animal Health (Ireland) is acquiring 100% of BioForLife Italia S.r.l in Milan, Italy. Italian FDI/Golden Power regulatory approval has now been received. The deal is expected to close within two months from September 8, 2026. All other terms from earlier disclosures remain unchanged.

Likely market impact

Regulatory clearance removes a key hurdle. Deal now expected to close within two months, giving clearer visibility on completion.